Assessing genomic instability (GI) by shallow whole-genome sequencing (sWGS) to predict PARP inhibitor (PARPi) response in metastatic castration-resistant prostate cancer (mCRPC). Homologous ...

Prevalence of EGFR Mutations in Patients With Resected Stage I to III Nonsquamous Non–Small Cell Lung Cancer: Results of India Cohort In total, 232 fellowship programs exist in the surveyed nations, ...

Progressive T cell exhaustion and predominance of aging tissue associated macrophages with advancing disease stage in penile squamous cell carcinoma.

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

A phase 2/3 multicenter trial evaluating safety and efficacy of a new mucoadhesive gemcitabine suspension for ablation of upper tract urothelial carcinoma. ABLE-22: Safety and efficacy evaluation of ...

CFO: Calibration-Free Odds Bayesian Designs for Dose Finding in Clinical Trials ...

DNA damage repair alterations as predictive biomarker for platinum-based chemotherapy in metastatic urothelial cancer.

CD39 expression as a predictive biomarker for neoadjuvant treatment in muscle-invasive bladder cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This ...

[99mTc]Tc-iPSMA SPECT/CT as an alternative to PET imaging for decision making in prostate cancer patients. PREP registry: Key findings. Total (n=4135) Cohort 1 (n=255): BF within 3 months from RP and ...

EPIC-B: Phase II trial of cemiplimab as first-line treatment in advanced penile carcinoma. Progressive T cell exhaustion and predominance of aging tissue associated macrophages with advancing disease ...